Has Andrew Adams, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,890 in general payments to Andrew Adams, MD across 199 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Adams, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Adams, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Adams, MD

Family Medicine · Slidell, LANPI 1013204742

Payments from drug & device makers

$3,890in general payments, 2019–2025

Across 199 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$799
Amgen$438
Lilly USA, LLC$264
UCB, Inc.$230
Novo Nordisk$194
ANI Pharmaceuticals, Inc.$190
plus $2K from 27 others

What the payments were for

Food & beverage$3,890100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	44	$799
Amgen	34	$438
Lilly USA, LLC	15	$264
UCB, Inc.	10	$230
Novo Nordisk	10	$194
ANI Pharmaceuticals, Inc.	9	$190
Mallinckrodt Hospital Products Inc.	7	$185
Cleerly, Inc.	1	$181
Axsome Therapeutics, Inc.	6	$161
AstraZeneca(2 entities)	8	$135
Johnson & Johnson	6	$113
Antares Pharma, Inc.	5	$113
GSK	5	$103
Pfizer	4	$87
Boehringer Ingelheim	5	$78
Tolmar, Inc.	4	$75
Almatica Pharma LLC	3	$69
Exact Sciences	3	$65
Supernus Pharmaceuticals, Inc.	2	$45
Astellas Pharma US Inc	2	$43
Sumitomo Pharma America, Inc.	2	$41
Lundbeck LLC	2	$37
Nevro Corp.	2	$36
Bioventus LLC	1	$29
Eisai Inc.	1	$24
Boston Scientific	1	$22
IBSA Pharma Inc.	1	$22
Aurinia Pharma U.S., Inc.	1	$19
Takeda Pharmaceuticals U.S.A., Inc.	1	$19
Ironwood Pharmaceuticals, Inc	1	$18
Philips North America LLC	1	$18
Esperion Therapeutics, Inc.	1	$17
Intra-sana Laboratories	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Cleerly Labs$181

How this compares

$3,890 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana →

Medicare billing

Part B allowed, 2024

$83,580

Medicare patients

230

Services billed

1,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	90	$123,000
MounjaroTirzepatide	88	$117,387
JardianceEmpagliflozin	71	$89,957
LinzessLinaclotide	52	$52,791
EliquisApixaban	52	$38,153
VraylarCariprazine Hcl	14	$22,801
MyrbetriqMirabegron	30	$21,915
RybelsusSemaglutide	13	$21,790
TrulicityDulaglutide	16	$16,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	23	$16,554
JanuviaSitagliptin Phosphate	14	$15,646
Breo ElliptaFluticasone/Vilanterol	23	$10,441
Combivent RespimatIpratropium/Albuterol Sulfate	20	$9,708
Xigduo XrDapaglifloz Propaned/Metformin	13	$7,598
Albuterol Sulfate HfaAlbuterol Sulfate	148	$5,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Rybelsus	$194	$144,790103 claims
Lilly USA, LLCMounjaro, Trulicity	$264	$134,311104 claims
Boehringer IngelheimJardiance, Combivent Respimat	$78	$99,66591 claims
AbbVieLinzess, Vraylar, Armour Thyroid	$799	$77,17084 claims
PfizerEliquis	$87	$38,15352 claims
GSKTrelegy Ellipta, Breo Ellipta	$103	$26,99446 claims
Astellas Pharma US IncMyrbetriq	$43	$21,91530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.